news
Regenxbio's gene therapy for diabetic retinopathy lasts three years
Regenxbio's single-dose gene therapy, Surabgene (lomparvovec), showed durable efficacy for three years in a Phase II trial for non-proliferative diabetic retinopathy. The study, presented at the Retina Society meeting, used an in-office eye injection to maintain vision improvements and reduce disease progression.
Regenxbio's single-dose gene therapy, Surabgene (lomparvovec), showed durable efficacy for three years in a Phase II trial for non-proliferative diabetic retinopathy. The study, presented at the Retina Society meeting, used an in-office eye injection to maintain vision improvements and reduce disease progression.
The architecture take
A single shot of gene therapy holding for three years? That’s not just good for eyes; it's a peek into a future where complex chronic conditions driven by metabolism, like diabetes, get one-and-done treatments. The mechanism here is about improving vascular health in the retina, essentially preventing the damage high blood sugar wreaks on tiny blood vessels and nerve tissue in the eye. I've been watching how these genetic fixes move from concept to actual human impact. This data, a long-term follow-up from the ALTITUDE study, isn't just about preserving eyesight. It hints at a future where we’re not just managing symptoms but hitting the root cause of metabolic breakdown with a single intervention. The payoff? Less chronic load on the system and fewer daily interventions. Watch for similar durable therapies targeting other tissues hit hard by systemic inflammation and metabolic dysregulation, from kidneys to peripheral nerves. The eye is often a bellwether for wider health. It means less time spent in doctors' offices and more stable health baselines. That's a net gain for anyone trying to keep their system regulated, not just their vision clear.